13 results on '"Merino-Lucas E"'
Search Results
2. Efectividad de la vacuna BNT162b2 para prevenir la COVID-19 en personal sanitario
- Author
-
Chico-Sánchez P, Gras-Valentí P, Algado-Sellés N, Merino-Lucas E, Rodríguez-Díaz JC, Ronda-Pérez E, Sánchez-Payá J, and Grupo COVID-19 de Medicina Preventiva
- Subjects
Immunogenicity vaccine ,SARS-CoV-2 ,Case?control studies ,Vacuna COVID-19 ,COVID-19 ,COVID-19 vaccines ,Inmunogenicidad vacunal ,Health personnel ,Personal sanitario ,Estudio de casos y controles - Abstract
OBJECTIVE: To assess the effectiveness of the vaccine against SARS-CoV-2 (BNT162b2) in healthcare personnel of a health department. METHOD: Test-negative case?control study. Healthcare personnel with suspected COVID-19 and healthcare personnel close contacts of COVID-19 cases were included between January 27th and June 6th, 2021. They were PCR tested for SARS-CoV-2; those with positive PCR were considered cases and those with negative PCR were considered controls. The adjusted vaccine effectiveness (aVE) to prevent COVID-19 cases and their 95% confidence interval (95%CI) were calculated using the formula VE=(1-odds ratio)×100. RESULTS: 624 healthcare personnel were included, of which 43 (6.9%) were considered cases and 581 (93.8%) controls. The aVE of the complete regimen was 96.3% (95%CI: 82.5?99.2). The aVE of the incomplete pattern was 68.0% (95%CI: 30.0?85.4). CONCLUSIONS: The administration of the complete pattern of BNT162b2 vaccine against SARS-CoV-2 is effective for the prevention of cases of COVID-19 in healthcare personnel.
- Published
- 2022
3. [Effectiveness of the first dose of BNT162b2 vaccine to preventing covid-19 in healthcare personnel.]
- Author
-
Gras-Valenti, P, Chico-Sanchez, P, Algado-Selles, N, Jimenez-Sepulveda, N, Gomez-Sotero, I, Fuster-Perez, M, Cartagena-Llopis, L, Sanchez-Valero, M, Cerezo-Milan, P, Martinez-Tornero, I, Tremino-Sanchez, L, Nadal-Morante, V, Monerris-Palmer, M, Esclapez-Martinez, A, MorenodeArcos-Fuentes, E, Escalada-Martin, I, Escribano-Canadas, I, Merino-Lucas, E, Rodriguez-Diaz, J, and Sanchez-Paya, J
- Subjects
Vaccine effectiveness ,Infection prevention and control ,SARS-CoV-2 ,Spain ,SARS-CoV-2 vaccine ,SARSCoV-2 vaccine ,COVID-19 ,Healthcare personnel - Abstract
OBJECTIVE: A first protective dose of vaccine may allow delaying the second dose in a context of low supply. The objective is to assess the effectiveness of a single dose of vaccine against SARS-CoV-2 (BNT162b2) after twelve days of its administration in healthcare personnel (HCP) of a Health Department. METHODS: A case-control study was made. HCP with suspected COVID-19 and HCP close contacts of COVID-19 cases were included between January 27 and February 7, 2021. They were PCR tested for SARS-CoV-2; those with positive PCR were considered cases and those with negative PCR were considered controls. The crude (VE) and adjusted (VEa) vaccine effectiveness to prevent COVID-19 cases and their 95% confidence interval were calculated using the formula VE = (1-Odds ratio) x 100. RESULTS: 268 HCP were included, of which 70 (26.1%) were considered cases and 198 (73.9%) controls. The frequency of vaccine exposure in cases was 55.7% vs. 69.7% in controls (p=0.035). The VEa of the first vaccine dose was 52.6% (95%CI: 1.1-77.3). The VEa in the subgroup of HCP studied for suspected disease was 74.6% (CI95%: 38.4-89.5). CONCLUSIONS: One dose of BNT162b2 vaccine against SARS-CoV-2 offers early protection after twelve days of administration. These data could be considered to adapt strategies and consider postponing the second dose in situations of limited vaccine supply in order to achieve the maximum number of people covered with a first dose. OBJETIVO: Una primera dosis de vacuna protectora permitiria aplazar la segunda dosis en un contexto de suministro escaso. El objetivo de este trabajo fue conocer la efectividad de una dosis de vacuna frente a SARS-CoV-2 (BNT162b2) tras doce dias de su administracion en personal sanitario (PS) de un Departamento de Salud. METODOS: Se realizo un estudio de casos y controles. Se incluyo a PS con sospecha de COVID-19 y PS que tuvo contactos estrechos con casos de COVID-19 entre el 27 de enero y el 7 de febrero de 2021. Se les realizo una PCR para determinar SARS-CoV-2; aquellos con PCR positiva fueron considerados casos y aquellos con PCR negativa fueron considerados controles. Se calculo la efectividad vacunal cruda (EV) y ajustada (EVa) para prevenir casos de COVID-19 y su intervalo de confianza al 95%, mediante la formula EV = (1-Odds ratio) x 100. RESULTADOS: Fueron incluidos 268 PS, de los cuales 70 (26,1%) fueron considerados casos y 198 (73,9%) controles. La frecuencia de exposicion a la vacuna en los casos fue del 55,7% frente al 69,7% en los controles (p=0,035). La EVa de la primera dosis de vacuna fue del 52,6% (IC95%: 1,1-77,3). La EVa en el subgrupo de PS estudiados por sospecha de enfermedad fue del 74,6% (IC95%: 38,4-89,5). CONCLUSIONES: Una dosis de vacuna BNT162b2 frente a SARS-CoV-2 ofrece proteccion temprana tras doce dias de su administracion. Estos datos podrian considerarse para adaptar estrategias y valorar aplazar la segunda dosis en situaciones de limitacion de suministro de vacuna, con el fin de conseguir el maximo numero de personas cubiertas con una primera dosis.
- Published
- 2021
4. Evaluation of the validity of Ag PANBIO-COVID19 in the diagnosis of SARS-CoV-2 infection in asymptomatic or mildly infected patients
- Author
-
Gras-Valenti P, Vidal I, Montiel-Higuero I, Escribano I, Algado-Selles N, Chico-Sanchez P, Ventero M, Jimenez-Sepulveda N, Molina-Pardines C, Merino-Lucas E, Sanchez-Paya J, and Rodriguez J
- Subjects
SARS- CoV-2 ,antigen ,diagnosis ,COVID-19 - Abstract
Objective. To assess the validity of SARS-CoV-2 Antigen (Ag) detection for the diagnosis of SARS-CoV-2 infection in mildly infected or asymptomatic patients. Material and methods. Observational study to evaluate diagnostic tests. Non-hospitalized patients with indication for diagnostic testing for SARS-CoV-2 infection were included. The diagnostic test to be evaluated was the determination of Ag and as a reference standard to determine the presence of viral RNA the RT-PCR was used. Results. A total of 494 patients were included. Of these 71.5% (353/494) had symptoms and 28.5% (141/494) were asymptomatic (presurgery screening (35/494) and confirmed case-contact (106/494). The overall sensitivity of the Ag test was 61.1% and the specificity was 99.7%. The sensitivity and specificity in the asymptomatic group were 40% and 100% respectively, and in the symptomatic group 63.5% and 99.6% respectively. In turn, the sensitivity and specificity in the group of symptomatic patients varied according to the time of symptom evolution: in patients with recent symptoms, they were 71.4% and 99.6% respectively, while in patients with symptoms of more than 5 days of evolution, they were 26.7% and 100% respectively. In all groups studied, the presence of antigen is associated with a high viral load (Ct
- Published
- 2021
5. Infective endocarditis in elderly and very elderly patients
- Author
-
Menchi-Elanzi M, Ramos-Rincon J, Merino-Lucas E, Reus-Banuls S, Torrus-Tendero D, Climent-Paya V, Boix V, and Portilla-Sogorb J
- Subjects
Elderly ,Bacterial endocarditis ,Very elderly ,Cardiovascular infection ,Mortality - Abstract
Aims To compare the clinical and epidemiological characteristics and the evolution of infective endocarditis in adults aged under 65 years, 65-79 years, and 80 years or older. Methods An observational retrospective cohort study in patients with infective endocarditis was performed in a public hospital in Spain from January 2013 to December 2017. Results Seventy-two patients were treated: 26 (36.1%) were under 65 years old, 28 (38.9%) were 65-79 years old, and 18 (25%) were aged 80 or older. Prosthetic valve endocarditis was less common in patients aged 65-79 years (3.6%) than in younger (23.1%; p=0.047) or older (38.9%; p=0.004) patients. In contrast, degenerative heart disease was more prevalent in the 65-79 year age group [64.3% compared to 15.4% (p
- Published
- 2020
6. Impact of the covid-19 pandemic on health care workers in a tertiary care hospital emergency department,Impacto de la pandemia de covid-19 en los trabajadores sanitarios del servicio de urgencias de un hospital terciario
- Author
-
Chico-Sánchez, P., Gras-Valentí, P., Mora-Muriel, J. G., Algado-Sellés, N., Sánchez-Payá, J., Llorens, P., Soler-Molina, V. M., Hernández-Maldonado, M., Lameiras-Acevedo, A. S., Jimenez Sepulveda, N., Gomez Sotero, I., Villanueva-Ruiz, C., Barrenengoa-Sañudo, J., Fuster-Pérez, M., Canovas-Javega, S., Cerezo-Milán, P., Monerris Palmer, M., Sánchez-Vela, P., Merino-Lucas, E., Rodríguez-Díaz, J. C., Gil-Carbonell, J., Sánchez-Martínez, R., Pastor-Cesteros, R., Mena-Esquivias Galiana-Ivars, L. M., Jaime-Sánchez, F., Margarit-Ferri, C., Javier González de Dios, and Lloret García-Alonso, G. m A.
7. [Positioning proposal on the recommendations for the use of masks in health centers after the cessation of the mandatory use in Spain].
- Author
-
Gras Valenti P, Sánchez Payá J, Rodríguez Díaz JC, Llorens Soriano P, Merino Lucas E, and Chico Sánchez P
- Subjects
- Humans, Spain, Pandemics prevention & control, SARS-CoV-2, COVID-19 prevention & control, Respiratory Tract Infections
- Abstract
Since the beginning of the COVID-19 pandemic in March 2020, the use of masks has been a fundamental pillar for controlling the transmission of SARS-CoV-2 in different areas. Its mandatory nature has been regulated by different regulations, and its effectiveness in reducing the transmission of SARS-CoV-2 and other respiratory viruses has been strongly proven. In this regard, the beneficial impact stands out in healthcare centers where it has been shown to reduce the transmission of respiratory infections, both in patients and healthcare professionals. This document proposes recommendations for the use of masks in health centers at the current time when we find ourselves with an end to the mandatory use of masks in Spain. They are aimed at healthcare professionals, patients and companions/visitors and aim to protect them from acquiring acute respiratory infections as a result of the complex relationships established in the healthcare field.
- Published
- 2024
8. The Waning of BNT162b2 Vaccine Effectiveness for SARS-CoV-2 Infection Prevention over Time: A Test-Negative Study in Health Care Professionals of a Health Department from January 2021 to December 2021.
- Author
-
Jiménez-Sepúlveda N, Chico-Sánchez P, Castro-García JM, Escribano-Cañadas I, Merino-Lucas E, Ronda-Pérez E, Sánchez-Payá J, Gras-Valentí P, and On Behalf Of The Covid-Preventive Medicine Group
- Subjects
- Humans, BNT162 Vaccine, COVID-19 Vaccines therapeutic use, Vaccine Efficacy, SARS-CoV-2, Health Personnel, COVID-19 epidemiology, COVID-19 prevention & control, Viral Vaccines
- Abstract
The duration of protection of vaccines against SARS-CoV-2 infection has been evaluated in previous studies, but uncertainty remains about the persistence of effectiveness over time and the ideal timing for booster doses. Therefore, the aim of this study was to evaluate BNT162b2 vaccine effectiveness against SARS-CoV-2 infection in health care workers (HCWs) at a tertiary hospital depending on time elapsed since the completion of a two-dose vaccination regimen. We conducted a case-control with negative test study between 25 January and 12 December 2021 that included 1404 HCWs who underwent an active infection diagnostic test (AIDT) to rule out SARS-CoV-2 infection due to COVID-19 suspicion or prior close contact with patients diagnosed with COVID-19. The adjusted vaccine effectiveness (aVE) for the prevention of SARS-CoV-2 infection 12 to 120 days after completing the full two-dose vaccination regimen was 91.9%. Then, aVE decreased to 63.7% between 121 to 240 days after completing the full two-dose regimen and to 37.2% after 241 days since the second dose. Vaccination against SARS-CoV-2 infection in HCWs remains highly effective after 12 to 120 days have elapsed since the administration of two doses of the BNT162b2 vaccine; however, effectiveness decreases as time elapses since its administration.
- Published
- 2022
- Full Text
- View/download PDF
9. [Effectiveness of BNT162b2 vaccine to preventing COVID-19 in healthcare personnel].
- Author
-
Chico-Sánchez P, Gras-Valentí P, Algado-Sellés N, Merino-Lucas E, Rodríguez-Díaz JC, Ronda-Pérez E, and Sánchez-Payá J
- Subjects
- BNT162 Vaccine, COVID-19 Vaccines, Delivery of Health Care, Health Personnel, Humans, SARS-CoV-2, COVID-19 epidemiology, COVID-19 prevention & control, Influenza Vaccines
- Abstract
Objective: To assess the effectiveness of the vaccine against SARS-CoV-2 (BNT162b2) in healthcare personnel of a health department., Method: Test-negative case̶control study. Healthcare personnel with suspected COVID-19 and healthcare personnel close contacts of COVID-19 cases were included between January 27th and June 6th, 2021. They were PCR tested for SARS-CoV-2; those with positive PCR were considered cases and those with negative PCR were considered controls. The adjusted vaccine effectiveness (aVE) to prevent COVID-19 cases and their 95% confidence interval (95%CI) were calculated using the formula VE=(1-odds ratio)×100., Results: 624 healthcare personnel were included, of which 43 (6.9%) were considered cases and 581 (93.8%) controls. The aVE of the complete regimen was 96.3% (95%CI: 82.5̶99.2). The aVE of the incomplete pattern was 68.0% (95%CI: 30.0̶85.4)., Conclusions: The administration of the complete pattern of BNT162b2 vaccine against SARS-CoV-2 is effective for the prevention of cases of COVID-19 in healthcare personnel., (Copyright © 2021 SESPAS. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
10. Effectivity of a Program for the Control and Prevention of COVID-19 Healthcare-Associated Infections in a Spanish Academic Hospital.
- Author
-
Gras-Valentí P, Mora-Muriel JG, Chico-Sánchez P, Algado-Sellés N, Soler-Molina VM, Hernández-Maldonado M, Lameiras-Azevedo AS, Jiménez Sepúlveda NJ, Gómez Sotero IL, Villanueva-Ruiz CO, Barrenengoa-Sañudo J, Fuster-Pérez M, Cánovas-Jávega S, Cerezo-Milan P, Monerris-Palmer M, Llorens-Soriano P, Merino-Lucas E, Rodríguez-Diaz JC, Gil-Carbonell J, Sánchez-Martínez R, Pastor-Cesteros R, Mena-Esquivias L, Galiana-Ivars M, Jaime-Sánchez FA, Margarit-Ferri C, Gonzalez-deDios J, Lloret G, García-Alonso MA, Sánchez-Vela P, and Sánchez-Payá J
- Subjects
- Adult, COVID-19 epidemiology, COVID-19 transmission, Cross Infection epidemiology, Female, Humans, Incidence, Infectious Disease Transmission, Patient-to-Professional statistics & numerical data, Male, Masks statistics & numerical data, Middle Aged, Personnel, Hospital statistics & numerical data, Program Evaluation, Risk Assessment statistics & numerical data, SARS-CoV-2 isolation & purification, Spain epidemiology, Academic Medical Centers, COVID-19 prevention & control, Cross Infection prevention & control, Infectious Disease Transmission, Patient-to-Professional prevention & control
- Abstract
Background: Although recommendations to prevent COVID-19 healthcare-associated infections (HAIs) have been proposed, data on their effectivity are currently limited., Objective: The aim was to evaluate the effectivity of a program of control and prevention of COVID-19 in an academic general hospital in Spain., Methods: We captured the number of COVID-19 cases and the type of contact that occurred in hospitalized patients and healthcare personnel (HCP). To evaluate the impact of the continuous use of a surgical mask among HCP, the number of patients with COVID-19 HAIs and accumulated incidence of HCP with COVID-19 was compared between the preintervention and intervention periods., Results: Two hundred fifty-two patients with COVID-19 have been admitted to the hospital. Seven of them had an HAI origin (6 in the preintervention period and 1 in the intervention period). One hundred forty-two HCP were infected with SARS-CoV-2. Of them, 22 (15.5%) were attributed to healthcare (2 in the emergency department and none in the critical care departments), and 120 (84.5%) were attributed to social relations in the workplace or during their non-work-related personal interactions. The accumulated incidence during the preintervention period was 22.3 for every 1000 HCP and 8.2 for every 1000 HCP during the intervention period. The relative risk was 0.37 (95% confidence interval, 0.25 to 0.55) and the attributable risk was -0.014 (95% confidence interval, -0.020 to -0.009)., Conclusions: A program of control and prevention of HAIs complemented with the recommendation for the continuous use of a surgical mask in the workplace and social environments of HCP effectively decreased the risk of COVID-19 HAIs in admitted patients and HCP., Competing Interests: The authors disclose no conflict of interest., (Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2021
- Full Text
- View/download PDF
11. [Effectiveness of the first dose of BNT162b2 vaccine to preventing covid-19 in healthcare personnel.]
- Author
-
Gras-Valentí P, Chico-Sánchez P, Algado-Sellés N, Jiménez-Sepúlveda NJ, Gómez-Sotero IL, Fuster-Pérez M, Cartagena-Llopis L, Sánchez-Valero M, Cerezo-Milán P, Martínez-Tornero I, Tremiño-Sánchez L, Nadal-Morante V, Monerris-Palmer M, Esclapez-Martínez A, MorenodeArcos-Fuentes E, Escalada-Martín I, Escribano-Cañadas I, Merino-Lucas E, Rodríguez-Díaz JC, and Sánchez-Payá J
- Subjects
- Adult, BNT162 Vaccine, COVID-19 diagnosis, COVID-19 Nucleic Acid Testing, Case-Control Studies, Female, Humans, Logistic Models, Male, Middle Aged, Spain, Treatment Outcome, COVID-19 prevention & control, COVID-19 Vaccines, Health Personnel
- Abstract
Objective: A first protective dose of vaccine may allow delaying the second dose in a context of low supply. The objective is to assess the effectiveness of a single dose of vaccine against SARS-CoV-2 (BNT162b2) after twelve days of its administration in healthcare personnel (HCP) of a Health Department., Methods: A case-control study was made. HCP with suspected COVID-19 and HCP close contacts of COVID-19 cases were included between January 27 and February 7, 2021. They were PCR tested for SARS-CoV-2; those with positive PCR were considered cases and those with negative PCR were considered controls. The crude (VE) and adjusted (VEa) vaccine effectiveness to prevent COVID-19 cases and their 95% confidence interval were calculated using the formula VE = (1-Odds ratio) x 100., Results: 268 HCP were included, of which 70 (26.1%) were considered cases and 198 (73.9%) controls. The frequency of vaccine exposure in cases was 55.7% vs. 69.7% in controls (p=0.035). The VEa of the first vaccine dose was 52.6% (95%CI: 1.1-77.3). The VEa in the subgroup of HCP studied for suspected disease was 74.6% (CI95%: 38.4-89.5)., Conclusions: One dose of BNT162b2 vaccine against SARS-CoV-2 offers early protection after twelve days of administration. These data could be considered to adapt strategies and consider postponing the second dose in situations of limited vaccine supply in order to achieve the maximum number of people covered with a first dose.
- Published
- 2021
12. Frequency, Associated Risk Factors, and Characteristics of COVID-19 Among Healthcare Personnel in a Spanish Health Department.
- Author
-
Algado-Sellés N, Gras-Valentí P, Chico-Sánchez P, Mora-Muriel JG, Soler-Molina VM, Hernández-Maldonado M, Lameiras-Azevedo AS, Jiménez-Sepúlveda NJ, Gómez-Sotero IL, Villanueva-Ruiz CO, Barrenengoa-Sañudo J, Fuster-Pérez M, Cánovas-Javega S, Cerezo-Milan P, Monerris-Palmer M, Esclapez A, Cartagena-Llopis L, García-Rivera C, Martínez-Tornero I, Nadal-Morante V, Merino-Lucas E, Rodriguez-Diaz JC, Vidal-Catala I, Llorens-Soriano P, San Inocencio D, Gil-Carbonell J, Montiel-Higuero I, Sánchez-Vela P, and Sánchez-Payá J
- Subjects
- Adult, Age Factors, Aged, COVID-19, Contact Tracing methods, Female, Humans, Male, Middle Aged, Occupations, Pandemics, Public Health Surveillance methods, Risk Factors, SARS-CoV-2, Severity of Illness Index, Sex Factors, Spain epidemiology, Tertiary Care Centers, Coronavirus Infections epidemiology, Health Personnel statistics & numerical data
- Abstract
Introduction: This study examines the frequency, associated factors, and characteristics of healthcare personnel coronavirus disease 2019 cases in a healthcare department that comprises a tertiary hospital and its associated 12 primary healthcare centers., Methods: This study included healthcare personnel that showed symptoms or were in contact with a coronavirus disease 2019 case patient from March 2, 2020 to April 19, 2020. Their evolution and characteristics (age, sex, professional category, type of contact) were recorded. Correlations between the different characteristics and risk of developing coronavirus disease 2019 and severe coronavirus disease 2019 were analyzed using chi-square tests. Their magnitudes were quantified with ORs, AORs, and their 95% CIs using a logistic regression model., Results: Of the 3,900 healthcare professionals in the department, 1,791 (45.9%) showed symptoms or were part of a contact tracing study. The prevalence of those with symptoms was 20.1% (784/3,900; 95% CI=18.8, 21.4), with coronavirus disease 2019 was 4.0% (156/3,900; 95% CI=3.4, 4.6), and with severe coronavirus disease 2019 was 0.5% (18/3,900; 95% CI=0.2, 0.7). The frequency of coronavirus disease 2019 in symptomatic healthcare personnel with a nonprotected exposure was 22.8% (112/491) and 13.7% (40/293) in those with a protected exposure (AOR=2.2, 95% CI=1.2, 3.9). The service in which the healthcare personnel performed their activity was not significantly associated with being diagnosed with coronavirus disease 2019. A total of 26.3% (10/38) of male healthcare personnel with coronavirus disease 2019 required hospitalization, compared with 6.8% (8/118) among female healthcare personnel (OR=4.9, 95% CI=1.8, 13.6)., Conclusions: A surveillance and monitoring program centred on healthcare personnel enables an understanding of the risk factors that lead to coronavirus disease 2019 among this population. This knowledge allows the refinement of the strategies for disease control and prevention in healthcare personnel during the coronavirus disease 2019 pandemic., (Copyright © 2020 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
13. [Association between inflammatory markers and microbial translocation in patients with human immunodeficiency virus infection taking antiretroviral treatment].
- Author
-
Reus Bañuls S, Portilla Sogorb J, Sanchez-Paya J, Boix Martínez V, Giner Oncina L, Frances R, Such J, Merino Lucas E, and Gimeno Gascón A
- Subjects
- Adult, Aged, Biomarkers, Cardiovascular Diseases epidemiology, Comorbidity, Cross-Sectional Studies, Diabetes Mellitus epidemiology, Dyslipidemias epidemiology, Female, HIV Infections drug therapy, HIV Infections epidemiology, HIV Infections microbiology, Hepatitis C, Chronic blood, Hepatitis C, Chronic epidemiology, Humans, Inflammation epidemiology, Inflammation microbiology, Male, Middle Aged, RNA, Bacterial genetics, RNA, Ribosomal, 16S genetics, Substance Abuse, Intravenous blood, Substance Abuse, Intravenous epidemiology, Young Adult, Anti-HIV Agents therapeutic use, Bacterial Translocation, Cytokines blood, DNA, Bacterial blood, DNA, Ribosomal blood, HIV Infections blood, Inflammation blood
- Abstract
Background and Objective: Inflammatory biomarkers are increased in patients with human immunodeficiency virus (HIV) infection. Antiretroviral treatment (ART) improves some parameters but do not normalize them. The aim of this study is to determine those factors (including microbial translocation) associated with higher inflammation in HIV treated patients., Patients and Methods: Transversal observational study., Inclusion Criteria: HIV patients receiving ART with an HIV viral load (VL)<400 copies/mL. Selection of patients: consecutively between November 2011 and January 2012. Main variable: plasma levels of interleukin 6 (IL-6) and tumour necrosis factor α (TNF-α). Main explanatory variable: microbial translocation markers (16S ribosomal DNA and sCD14). Patients with IL-6 or TNF-α levels above percentile 75 (group 1) were compared with the rest of patients (group 2). Odds ratio (OR) were determined., Results: Eighty-one patients were included (73% male, median age 45 years, 48% stage C). Twenty-six percent had chronic hepatitis C. Median CD4 cell was 493/mm(3) and 30% had detectable HIV VL. 16S ribosomal DNA was detected in 21% of patients. Factors associated with the higher levels of inflammatory markers were 16S ribosomal DNA (OR 77, P<.0001), sCD14 levels (P<.0001) and history of cardiovascular disease (OR 15, P<.01). In multivariate analysis, associations remained for 16S ribosomal DNA (OR 62, P<.0001) and previous cardiovascular disease (OR 25, P<.01)., Conclusions: In patients with HIV infection receiving treatment, the higher levels of inflammatory markers are associated with microbial translocation and past cardiovascular events., (Copyright © 2013 Elsevier España, S.L. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.